RHB Investment Research Reports

KPJ Healthcare - A Seasonally Quiet Quarter; Maintain BUY

Publish date: Tue, 28 May 2024, 11:25 AM
0 3,838
An official blog in I3investor to publish research reports provided by RHB Research team.

All materials published here are prepared by RHB Investment Bank Bhd. For latest offers on RHB Invest trading products and news, please refer to: http://www.rhbinvest.com

RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur

Tel : +(60) 3 9280 8888
Fax : +(60) 3 9200 2216
  • Maintain BUY and MYR2.12 TP, 6% upside. KPJ Healthcare reported 1Q24 core earnings of MYR51m, down by 6% YoY and accounting for 17% and 18% of our and Street’s expectations – we deem this as in line, as we expect stronger quarters ahead. Hospitals under gestation continue to deliver robust improvements in operating metrics on top of narrowing losses. Our DCF-derived TP represents 15x 2024F EV/EBITDA or 2SD above its 5-year historical EV/EBITDA average of 12x. We incorporate a 0% ESG premium/discount given KPJ’s 3.0 ESG score.
  • Results overview. 1Q24 core profit slipped 39% QoQ due to a seasonally weaker quarter. We deem the results as in line, as we expect stronger quarters ahead – underpinned by improved operating efficiency of hospitals under gestation, robust patient traffic growth, and pick-up in foreign patient visits. Revenue grew 11% on a better patient mix, ie inpatient and outpatient visits booked +3.4% and -2.1% YoY growth. Damansara Specialist Hospital 2 showed significant improvement, with LBITDA narrowing to MYR0.6m from of MYR10m a year ago (LBT narrowed to MYR12-14m from c.MYR20m previously). During the quarter, KPJ registered provisional extinguishment of net liabilities amounting to MYR43.3m as a result of the disposal of the aged care business in Australia. This figure was excluded at core profit level (MYR25m after adjusting for its 57% stake in Jeta Garden). The board has declared an interim dividend of MYR0.01, up from 0.6 sen in 1Q23.
  • Operating metrics and margin. KPJ’s outpatient and inpatient visits were lowered by 6% and 4% QoQ to 717,648 and 91,039, bringing total patient visits to 808,687 (-5.7% QoQ) on the back of a seasonally weaker quarter. The bed occupancy rate (BOR) was lowered 4ppts QoQ (lowered 5ppts YoY) to 65% on the opening of new beds (+50 QoQ, +277 YoY). Correspondingly, Malaysia operations’ EBITDA margin was lower by 1.6ppts QoQ to 21.2%, likely driven by higher opex in relation to the opening of new beds.
  • Earnings revision. Post result, we keep our earnings estimate unchanged pending an analysts briefings today.
  • Valuation. Maintain BUY and MYR2.12 TP (DCF), which implies 15x 2024F EV/EBITDA or 2SD above its 5-year historical average of 12x. Our basis of premium valuation on KPJ is premised on the group’s solid turnaround storey, which offers: i) Room for margins improvement from hospitals under gestation period, ii) potential opportunity to be unlocked via expansion into the health tourism segment, and iii) a strategic move in upscaling an existing hospital into tertiary care centre – enabling KPJ to tap into more complex and uncommon procedures. Key downside risks: Lower-than-expected patient visits/revenue intensity growth and higher-than-expected operating costs.

Source: RHB Research - 28 May 2024

Related Stocks
Be the first to like this. Showing 0 of 0 comments

Post a Comment